ConfluencePharmaceuticals 认领应用

Confluence Pharmaceuticals is the exclusive licensee of aclinically discovered, novel therapeutic treatment for core social and communication impairments in individuals suffering from Autism Spectrum Disorders (ASD) and Fragile X Syndrome (FXS). There is no FDA approved medication for these life-long impairments. According to published studies, the potential success of a therapeutic drug could reduce the cost of life-long care by as much as two-thirds.